Eli Lilly and Company (NYSE:LLY) announced Tuesday that it will acquire Curevo Inc., LimmaTech Biologics AG and Vaccine Company, Inc. as the drugmaker expands its infectious disease research portfolio.

The acquisitions strengthen Eli Lilly’s strategy of investing in vaccine and prevention technologies aimed at reducing long-term disease risks tied to infections, including neurological disorders, cancer and antimicrobial-resistant bacterial diseases.

“For 150 years, Lilly has advanced medicines to address the world’s most pressing health challenges,” the company said, adding that infectious diseases remain a major source of global morbidity and long-term health complications.

Eli Lilly Targets Long-Term Disease Prevention

Daniel Skovronsky, Lilly’s chief scientific and product officer and president of Lilly Research Laboratories, said the acquisitions support a broader prevention-focused strategy.

“These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences,” Skovronsky said. “Decades of evidence now link common infections to diseases that potentially emerge years later, including neurological disease, cancer and infertility.”

Deal Terms And Vaccine Pipeline Expansion

Curevo’s lead candidate, amezosvatein, is a shingles vaccine currently in Phase 2 development. Eli Lilly said the vaccine showed comparable immune responses to the current standard of care while reducing side effects such as fatigue, chills and injection-site pain by more than half. Eli Lilly said Curevo shareholders could receive up to $1.5 billion in cash tied to upfront and milestone payments.

LimmaTech Biologics develops vaccines targeting drug-resistant bacterial pathogens, including Staphylococcus aureus, Neisseria gonorrhoeae and Chlamydia trachomatis. Eli Lilly said the acquisition could total up to $780 million.

Vaccine Company is developing nanoparticle-based vaccine technologies, including an Epstein-Barr Virus vaccine candidate. Eli Lilly said the deal could reach $1.55 billion in milestone-based payments.

The transactions remain subject to customary closing conditions and regulatory approvals.

LLY Technical Analysis: Bullish Trend Above Key Moving Averages

Eli Lilly’s stock has shown strong performance over the past year, with a 12-month gain of 46.85%. The current price of $1079.40 is significantly above key moving averages, including 10.6% above the 20-day simple moving average (SMA) and 16.1% above the 200-day SMA, indicating a bullish trend.

  • Key Resistance: $1095.50 — a nearby level where rebounds can stall.
  • Key Support: $943.50 — a nearby level where buyers previously stepped in.

The stock’s momentum is currently best assessed through the MACD, which is above its signal line, indicating that bullish pressure is building. This suggests that the upward trend is likely to continue unless there are significant changes in market conditions.

Eli Lilly Earnings Preview And Analyst Outlook

Eli Lilly is slated to provide its next financial update on August 6, 2026 (estimated).

  • EPS Estimate: 880 cents (Up from 631 cents YoY)
  • Revenue Estimate: $20.43 billion (Up from $15.56 billion YoY)
  • Valuation: P/E of 37.8x (Indicates premium valuation)

Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price forecast of $1241.00. Recent analyst moves include:

  • Barclays: Overweight (Raises forecast to $1400.00) (May 5)
  • Guggenheim: Buy (Maintains forecast to $1183.00) (May 5)
  • Wolfe Research: Outperform (Maintains forecast to $1325.00) (May 4)

LLY Price Action: Eli Lilly shares were up 1.28% at $1078.66 at the time of publication on Tuesday, according to Benzinga Pro data.

Photo via Shutterstock